MX2015012429A - Compuestos heterociclicos y sus usos. - Google Patents
Compuestos heterociclicos y sus usos.Info
- Publication number
- MX2015012429A MX2015012429A MX2015012429A MX2015012429A MX2015012429A MX 2015012429 A MX2015012429 A MX 2015012429A MX 2015012429 A MX2015012429 A MX 2015012429A MX 2015012429 A MX2015012429 A MX 2015012429A MX 2015012429 A MX2015012429 A MX 2015012429A
- Authority
- MX
- Mexico
- Prior art keywords
- heterocyclic compounds
- preparation
- methods
- pharmaceutical formulations
- certain pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporcionan ciertas formulaciones farmacéuticas de omecamtiv mecarbil y métodos para su preparación y uso.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361785763P | 2013-03-14 | 2013-03-14 | |
| PCT/US2014/027104 WO2014152236A1 (en) | 2013-03-14 | 2014-03-14 | Heterocyclic compounds and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015012429A true MX2015012429A (es) | 2016-04-07 |
Family
ID=50549466
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015012429A MX2015012429A (es) | 2013-03-14 | 2014-03-14 | Compuestos heterociclicos y sus usos. |
| MX2015012414A MX363347B (es) | 2013-03-14 | 2014-03-14 | Sal de omecamtiv mecarbilo y proceso para preparar la sal. |
| MX2021001231A MX2021001231A (es) | 2013-03-14 | 2015-09-11 | Compuestos heterociclicos y sus usos. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015012414A MX363347B (es) | 2013-03-14 | 2014-03-14 | Sal de omecamtiv mecarbilo y proceso para preparar la sal. |
| MX2021001231A MX2021001231A (es) | 2013-03-14 | 2015-09-11 | Compuestos heterociclicos y sus usos. |
Country Status (42)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ552404A (en) | 2004-06-17 | 2010-04-30 | Cytokinetics Inc | Compounds, compositions and methods |
| EP2968173B1 (en) * | 2013-03-14 | 2020-10-14 | Amgen Inc. | Heterocyclic compounds and their uses |
| TWI790189B (zh) | 2015-01-02 | 2023-01-21 | 美商梅拉洛伊卡公司 | 細菌組成物 |
| WO2016210240A1 (en) | 2015-06-26 | 2016-12-29 | Amgen Inc. | Combination therapy of cardiac myosin activator and sinus node if current inhibitor |
| AU2018290983B2 (en) | 2017-06-30 | 2023-11-23 | Amgen Inc. | Methods of treating heart failure with cardiac sarcomere activators |
| EP4265597A3 (en) * | 2017-06-30 | 2023-11-22 | Amgen Inc. | Synthesis of omecamtiv mecarbil |
| EA039850B1 (ru) * | 2018-04-30 | 2022-03-21 | Эмджен Инк. | Синтез омекамтива мекарбила |
| EP3594199B1 (en) | 2018-07-09 | 2020-07-01 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof |
| WO2020014406A1 (en) | 2018-07-12 | 2020-01-16 | Assia Chemical Industries Ltd. | Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl |
| WO2020037164A1 (en) * | 2018-08-17 | 2020-02-20 | Amgen Inc. | Salts and crystal forms of omecamtiv mecarbil |
| US12442027B2 (en) | 2018-12-18 | 2025-10-14 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| PH12021552190A1 (en) | 2019-03-12 | 2022-08-22 | Amgen Inc | Polymorphs and cocrystals of a cardiac troponin activator |
| US20220185791A1 (en) * | 2019-03-12 | 2022-06-16 | Amgen Inc. | Polymorphs of a cardiac troponin activator |
| WO2021053175A1 (en) | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| US20220340542A1 (en) | 2019-09-19 | 2022-10-27 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| EP4041198A4 (en) * | 2019-10-09 | 2023-08-16 | Dr. Reddy's Laboratories Limited | SOLID FORMS OF OMECAMTIV MECARBIL DIHYDROCHLORIDE AND PROCESS THEREOF |
| AU2021221106A1 (en) | 2020-02-10 | 2022-09-22 | Amgen Inc. | Omecamtiv mecarbil tablet |
| JP2022039996A (ja) * | 2020-08-26 | 2022-03-10 | アムジエン・インコーポレーテツド | Ｍｃｌ－１阻害剤処方物 |
| MX2023005455A (es) | 2020-11-12 | 2023-07-27 | Amgen Inc | Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil. |
| WO2022177927A1 (en) | 2021-02-16 | 2022-08-25 | Assia Chemical Industries Ltd | Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt |
| US11702380B2 (en) | 2021-03-10 | 2023-07-18 | Amgen Inc. | Synthesis of omecamtiv mecarbil |
| WO2024081611A1 (en) | 2022-10-11 | 2024-04-18 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
| US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2788775B1 (fr) | 1999-01-22 | 2001-04-13 | Pf Medicament | Nouvelles n-alcoyl-n-[1-(omega-(arylalcoyloxy)alcoyl] piperidin-4-yl]-4h-3,1-benzo(thia/oxa)zines-2-amines substituees, leur preparation et leur application en therapeutique |
| GEP20043334B (en) | 1999-12-23 | 2004-03-10 | Pfizer Prod Inc | Hydrogel-Driven Drug Dosage Form |
| GB0124455D0 (en) | 2001-10-11 | 2001-12-05 | Pfizer Ltd | Pharmaceutical formulations |
| EP1438043A2 (en) | 2001-10-17 | 2004-07-21 | Aventis Pharma Deutschland GmbH | Method of reducing type 2 diabetes in high risk patients |
| US20050096365A1 (en) | 2003-11-03 | 2005-05-05 | David Fikstad | Pharmaceutical compositions with synchronized solubilizer release |
| NZ552404A (en) * | 2004-06-17 | 2010-04-30 | Cytokinetics Inc | Compounds, compositions and methods |
| WO2007054975A1 (en) | 2005-11-08 | 2007-05-18 | Panacea Biotec Ltd | Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders |
| PE20100743A1 (es) | 2005-11-15 | 2010-11-25 | Glaxo Group Ltd | Nuevos procedimientos y formulaciones |
| WO2007070683A2 (en) | 2005-12-15 | 2007-06-21 | Cytokinetics, Inc. | Certain chemical entities, compositions and methods |
| US20070208000A1 (en) | 2005-12-15 | 2007-09-06 | Morgan Bradley P | Certain chemical entities, compositions and methods |
| WO2007078839A2 (en) * | 2005-12-19 | 2007-07-12 | Cytokinetics, Inc. | Compounds, compositions and methods |
| US7639112B2 (en) | 2007-04-25 | 2009-12-29 | Sony Corporation | Fuse device with integrated switch |
| US20090192168A1 (en) * | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
| TW201006816A (en) * | 2008-05-15 | 2010-02-16 | Organon Nv | Hexafluoroisopropanol derivatives |
| US9492468B2 (en) | 2008-10-03 | 2016-11-15 | Pericor Therapeutics, Inc. | Methods and compositions for treatment of acute heart failure |
| US9253433B2 (en) | 2012-11-27 | 2016-02-02 | International Business Machines Corporation | Method and apparatus for tagging media with identity of creator or scene |
| EP2968173B1 (en) | 2013-03-14 | 2020-10-14 | Amgen Inc. | Heterocyclic compounds and their uses |
| MX2015012416A (es) * | 2013-03-14 | 2016-04-07 | Amgen Inc | Compuestos heterociclicos y sus usos. |
| WO2016123291A1 (en) | 2015-01-29 | 2016-08-04 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| WO2016210240A1 (en) | 2015-06-26 | 2016-12-29 | Amgen Inc. | Combination therapy of cardiac myosin activator and sinus node if current inhibitor |
| EP4265597A3 (en) | 2017-06-30 | 2023-11-22 | Amgen Inc. | Synthesis of omecamtiv mecarbil |
| AU2018290983B2 (en) | 2017-06-30 | 2023-11-23 | Amgen Inc. | Methods of treating heart failure with cardiac sarcomere activators |
| EP3594199B1 (en) | 2018-07-09 | 2020-07-01 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Crystalline 2-fluoro-3-nitrotoluene and process for the preparation thereof |
| WO2020014406A1 (en) | 2018-07-12 | 2020-01-16 | Assia Chemical Industries Ltd. | Solid state forms of omecamtiv mecarbil & omecamtiv mecarbil dihcl |
| WO2020037164A1 (en) | 2018-08-17 | 2020-02-20 | Amgen Inc. | Salts and crystal forms of omecamtiv mecarbil |
| US12442027B2 (en) | 2018-12-18 | 2025-10-14 | Amgen Inc. | Method of reducing aromatic nitro compounds |
| US20220340542A1 (en) | 2019-09-19 | 2022-10-27 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| WO2021053175A1 (en) | 2019-09-19 | 2021-03-25 | Synthon B.V. | Salts of omecamtiv mecarbil and solid forms thereof |
| US20220411374A1 (en) | 2019-10-09 | 2022-12-29 | Dr. Reddy's Laboratories Limited | Alternate processes for the preparation of omecamtiv mecarbil |
| EP4041198A4 (en) | 2019-10-09 | 2023-08-16 | Dr. Reddy's Laboratories Limited | SOLID FORMS OF OMECAMTIV MECARBIL DIHYDROCHLORIDE AND PROCESS THEREOF |
| WO2021136477A1 (zh) | 2020-01-03 | 2021-07-08 | 苏州科睿思制药有限公司 | 化合物i二盐酸盐的共晶及其制备方法和用途 |
| AU2021221106A1 (en) | 2020-02-10 | 2022-09-22 | Amgen Inc. | Omecamtiv mecarbil tablet |
| MX2023005455A (es) | 2020-11-12 | 2023-07-27 | Amgen Inc | Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil. |
| WO2022177927A1 (en) | 2021-02-16 | 2022-08-25 | Assia Chemical Industries Ltd | Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt |
| US11702380B2 (en) | 2021-03-10 | 2023-07-18 | Amgen Inc. | Synthesis of omecamtiv mecarbil |
| US11986474B1 (en) | 2023-06-27 | 2024-05-21 | Cytokinetics, Incorporated | Methods for treating heart failure by administering cardiac sarcomere activators |
-
2014
- 2014-03-14 EP EP14719472.4A patent/EP2968173B1/en active Active
- 2014-03-14 HU HUE14719472A patent/HUE052355T2/hu unknown
- 2014-03-14 PL PL14719472T patent/PL2968173T3/pl unknown
- 2014-03-14 SG SG11201507258PA patent/SG11201507258PA/en unknown
- 2014-03-14 MY MYPI2019004869A patent/MY204971A/en unknown
- 2014-03-14 US US14/773,436 patent/US9988354B2/en active Active
- 2014-03-14 DK DK14720369.9T patent/DK2970123T3/da active
- 2014-03-14 AU AU2014240049A patent/AU2014240049C1/en active Active
- 2014-03-14 UY UY0001035449A patent/UY35449A/es active IP Right Grant
- 2014-03-14 NZ NZ711225A patent/NZ711225A/en unknown
- 2014-03-14 UA UAA201509685A patent/UA117011C2/uk unknown
- 2014-03-14 WO PCT/US2014/027146 patent/WO2014152270A1/en not_active Ceased
- 2014-03-14 KR KR1020227007907A patent/KR102474467B1/ko active Active
- 2014-03-14 ES ES14720369T patent/ES2750676T3/es active Active
- 2014-03-14 CA CA2902646A patent/CA2902646C/en active Active
- 2014-03-14 SM SM20190563T patent/SMT201900563T1/it unknown
- 2014-03-14 JP JP2016502336A patent/JP6498658B2/ja active Active
- 2014-03-14 PT PT147203699T patent/PT2970123T/pt unknown
- 2014-03-14 CN CN201480014897.1A patent/CN105120844A/zh active Pending
- 2014-03-14 RS RS20191313A patent/RS59536B1/sr unknown
- 2014-03-14 PH PH1/2019/500176A patent/PH12019500176B1/en unknown
- 2014-03-14 MA MA44637A patent/MA44637B1/fr unknown
- 2014-03-14 SI SI201431724T patent/SI2968173T1/sl unknown
- 2014-03-14 TW TW103109296A patent/TWI667026B/zh active
- 2014-03-14 HR HRP20201967TT patent/HRP20201967T1/hr unknown
- 2014-03-14 JP JP2016502348A patent/JP6783138B2/ja active Active
- 2014-03-14 BR BR112015023417-8A patent/BR112015023417B1/pt active IP Right Grant
- 2014-03-14 MX MX2015012429A patent/MX2015012429A/es unknown
- 2014-03-14 HU HUE14720369A patent/HUE046285T2/hu unknown
- 2014-03-14 CA CA3147180A patent/CA3147180C/en active Active
- 2014-03-14 SM SM20200685T patent/SMT202000685T1/it unknown
- 2014-03-14 AR ARP140101155A patent/AR095542A1/es not_active Application Discontinuation
- 2014-03-14 MY MYPI2015002299A patent/MY186048A/en unknown
- 2014-03-14 MA MA38399A patent/MA38399B2/fr unknown
- 2014-03-14 HK HK16106250.4A patent/HK1218080A1/zh unknown
- 2014-03-14 AU AU2014239995A patent/AU2014239995B2/en active Active
- 2014-03-14 CN CN201810812212.8A patent/CN108785265B/zh active Active
- 2014-03-14 CN CN201480018405.6A patent/CN105209437B/zh active Active
- 2014-03-14 DK DK14719472.4T patent/DK2968173T3/da active
- 2014-03-14 BR BR112015022857-7A patent/BR112015022857B1/pt active IP Right Grant
- 2014-03-14 ES ES14719472T patent/ES2837038T3/es active Active
- 2014-03-14 EP EP14720369.9A patent/EP2970123B2/en active Active
- 2014-03-14 EA EA201591728A patent/EA031185B1/ru unknown
- 2014-03-14 MX MX2015012414A patent/MX363347B/es unknown
- 2014-03-14 KR KR1020157025283A patent/KR102374159B1/ko active Active
- 2014-03-14 PL PL14720369T patent/PL2970123T3/pl unknown
- 2014-03-14 PT PT147194724T patent/PT2968173T/pt unknown
- 2014-03-14 PE PE2015002000A patent/PE20151786A1/es unknown
- 2014-03-14 RU RU2015143643A patent/RU2663663C2/ru active
- 2014-03-14 EP EP20201011.2A patent/EP3821882A1/en active Pending
- 2014-03-14 AP AP2015008789A patent/AP2015008789A0/xx unknown
- 2014-03-14 SI SI201431358T patent/SI2970123T1/sl unknown
- 2014-03-14 US US14/210,713 patent/US9951015B2/en active Active
- 2014-03-14 LT LT14720369T patent/LT2970123T/lt unknown
- 2014-03-14 ME MEP-2019-283A patent/ME03566B/me unknown
- 2014-03-14 LT LTEP14719472.4T patent/LT2968173T/lt unknown
- 2014-03-14 HR HRP20191728 patent/HRP20191728T1/hr unknown
- 2014-03-14 RS RS20201513A patent/RS61215B1/sr unknown
- 2014-03-14 SG SG10201706656RA patent/SG10201706656RA/en unknown
- 2014-03-14 WO PCT/US2014/027104 patent/WO2014152236A1/en not_active Ceased
- 2014-03-16 JO JOP/2014/0114A patent/JOP20140114B1/ar active
-
2015
- 2015-08-24 IL IL240788A patent/IL240788B/en active IP Right Grant
- 2015-08-31 TN TN2015000380A patent/TN2015000380A1/en unknown
- 2015-09-03 IL IL24108915A patent/IL241089B/en active IP Right Grant
- 2015-09-08 PH PH12015501998A patent/PH12015501998B1/en unknown
- 2015-09-11 MX MX2021001231A patent/MX2021001231A/es unknown
- 2015-09-14 SA SA515361088A patent/SA515361088B1/ar unknown
- 2015-09-14 CL CL2015002708A patent/CL2015002708A1/es unknown
- 2015-10-13 CR CR20150549A patent/CR20150549A/es unknown
-
2018
- 2018-03-20 US US15/926,411 patent/US10421726B2/en active Active
- 2018-04-26 US US15/963,529 patent/US20180312469A1/en not_active Abandoned
- 2018-11-15 JP JP2018214801A patent/JP6689942B2/ja active Active
-
2019
- 2019-09-23 US US16/579,360 patent/US11384053B2/en active Active
- 2019-10-15 CY CY20191101080T patent/CY1122695T1/el unknown
- 2019-11-14 US US16/684,216 patent/US20200079736A1/en not_active Abandoned
-
2020
- 2020-04-08 JP JP2020069487A patent/JP6966590B2/ja active Active
- 2020-07-02 US US16/920,155 patent/US20200331859A1/en not_active Abandoned
- 2020-07-02 US US16/920,144 patent/US11472773B2/en active Active
- 2020-12-15 CY CY20201101184T patent/CY1123633T1/el unknown
-
2021
- 2021-09-24 US US17/448,833 patent/US11958809B2/en active Active
- 2021-10-21 JP JP2021172324A patent/JP7174132B2/ja active Active
-
2022
- 2022-06-08 US US17/806,033 patent/US11884630B2/en active Active
- 2022-09-08 US US17/930,695 patent/US20230044617A1/en not_active Abandoned
-
2023
- 2023-06-01 AR ARP230101396A patent/AR129504A2/es unknown
- 2023-11-27 US US18/520,156 patent/US12221417B2/en active Active
- 2023-12-06 US US18/531,424 patent/US12275704B2/en active Active
-
2024
- 2024-01-24 US US18/421,849 patent/US20240317687A1/en active Pending
- 2024-12-20 US US18/990,483 patent/US20250243163A1/en active Pending
-
2025
- 2025-01-17 US US19/029,911 patent/US20250376444A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021001231A (es) | Compuestos heterociclicos y sus usos. | |
| MX2015012416A (es) | Compuestos heterociclicos y sus usos. | |
| MX2020005181A (es) | Derivados de aminopiridina como inhibidores de cinasas de la familia de tyro3, axl y mer (tam). | |
| IL240291B (en) | History of pyridazinone and pharmaceutical preparations containing them | |
| IL240290B (en) | History of pyridazinone-amide and pharmaceutical preparations containing them | |
| MX2015012456A (es) | Compuestos heterociclicos y usos de los mismos. | |
| LT2829539T (lt) | Nauji pirolo dariniai, jų gamybos būdas ir juos turinčios farmacinės kompozicijos | |
| IL264259A (en) | Oral formulations of pyrrolidine derivatives | |
| IL243608A0 (en) | Substances with antiviral activity, preparations containing them and their uses | |
| MX2020001756A (es) | Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos. | |
| MX2020004205A (es) | Composiciones antibioticas de ceftolozano. | |
| EP3038465A4 (en) | Oral pharmaceutical formulation of omarigliptin | |
| CL2017000587A1 (es) | Derivados de tetrahidroquinolina como inhibidores de bromodominio | |
| EP3049389A4 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| UY34829A (es) | Nueva dosificación y formulación | |
| IL240875A0 (en) | Heterocyclic compounds and pharmaceutical preparations containing them | |
| EP3049077A4 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| PL3143032T3 (pl) | Nowe pochodne oksazafosforyn i ich zastosowania terapeutyczne | |
| EP2945703A4 (en) | ALBU-BCHE FORMULATIONS, PREPARATION THEREOF AND USES THEREOF | |
| EP3052475A4 (en) | Pharmaceutical use of 3-benzylsulfonylpropionitrile | |
| GEP20207208B (en) | Delayed release drug formulation | |
| TWD173316S (zh) | 義肢 | |
| MY180947A (en) | Ceftolozane antibiotic compositions |